Scott M. Giacobello net worth and biography

Scott Giacobello Biography and Net Worth

CFO of Aadi Bioscience

Prior to joining Aadi in 2021, Mr. Giacobello’s background included fulfilling key financial and operational roles with a long history of leadership in commercial stage growth companies. He played a key role in the buildout of U.S. operations and commercial readiness in his role as CFO at GW Pharmaceuticals, leading the Company’s financial strategy and raising more than $620 million ahead of their acquisition by Jazz Pharmaceuticals in 2021. He had previously served as the CFO of Chase Pharmaceuticals prior to their acquisition by Allergan, where he served in executive roles in corporate finance and global research and development.

What is Scott M. Giacobello's net worth?: The estimated net worth of Scott M. Giacobello is at least $1.50 million as of April 16th, 2026. Mr. Giacobello owns 295,224 shares of Aadi Bioscience stock worth more than $1,499,738 as of August 26th. This net worth estimate does not reflect any other assets that Mr. Giacobello may own. Learn More about Scott M. Giacobello's net worth.
How do I contact Scott M. Giacobello?: The corporate mailing address for Mr. Giacobello and other Aadi Bioscience executives is 9987 Carver Rd, Blue Ash, Ohio 45242-5550. Aadi Bioscience can also be reached via phone at (424) 473-8055 and via email at [email protected]. Learn More on Scott M. Giacobello's contact information.
Has Scott M. Giacobello been buying or selling shares of Aadi Bioscience?: Scott M. Giacobello has not been actively trading shares of Aadi Bioscience within the last three months. Most recently, Scott M. Giacobello sold 2,806 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $2.35, for a transaction totalling $6,594.10. Following the completion of the sale, the chief financial officer now directly owns 23,944 shares of the company's stock, valued at $56,268.40. Learn More on Scott M. Giacobello's trading history.
Who are Aadi Bioscience's active insiders?: Aadi Bioscience's insider roster includes Caley Castelein (Director), and Scott Giacobello (CFO). Learn More on Aadi Bioscience's active insiders.
Are insiders buying or selling shares of Aadi Bioscience?: During the last twelve months, insiders at the sold shares 1 times. They sold a total of 1,000 shares worth more than $389,830.00. The most recent insider tranaction occured on July, 13th when Director Karen Golz sold 1,000 shares worth more than $389,830.00. Insiders at Aadi Bioscience own 37.3% of the company. Learn More about insider trades at Aadi Bioscience.
Information on this page was last updated on 7/13/2026.

Scott M. Giacobello Insider Trading History at Aadi Bioscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/3/2025	Sell	2,806	$2.35	$6,594.10	23,944

Scott M. Giacobello Buying and Selling Activity at Aadi Bioscience

Aadi Bioscience Company Overview

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Today's Range

Now: $5.08

$4.89

$5.09

50 Day Range

MA: $4.22

$3.66

$4.88

2 Week Range

Now: $5.08

$1.21

$3.81

Volume

167,965 shs

Average Volume

261,100 shs

Market Capitalization

$125.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68